Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals
Rita Freitas, Tiago Barroso, Sofía Braga, Catarina C Santos et autres
BACKGROUND: The treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) (ribociclib, palbociclib, and abemaciclib) combined with endocrine therapy (ET) has become the standard of care (SoC) for first-line treatment in patients with metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative …
pt, br, us (code pays fourni par la source)
0 citations
Cureus